Oligodendroglial tumors

References

• Bailey P, Cushing H. A Classification of Tumors of the Glioma Group. Lippincott, PA, USA (1926).
   Google Scholar
• Kernohan JW, Mabon RF, Svien HJ et al. A simplified classification of the gliomas. Symposium on a new simplified concept of gliomas. Mayo Clin. Proc.25, 71–75 (1949).
   Google Scholar
• Kleihues P, Louis DN, Rosenblum MK et al. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol.61(3), 215–225 (2002).
   PubMed Web of Science ®Google Scholar
• Daumas-Duport C, Scheithauer BW, Kelly PJ. A histologic and cytologic method for the spatial definition of gliomas. Mayo Clin. Proc.62, 435–449 (1987).
   PubMed Web of Science ®Google Scholar
• Zulch KJ. Historical development of the classification of brain tumours and the new proposal of the World Health Organization (WHO). Neurosurg. Rev.4(3), 123–127 (1981).
   PubMedGoogle Scholar
• Kraus JA, Koopman J, Kaskel P et al. Shared allelic loss on chromosome 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J. Neuropathol.Exp. Neurol.54, 91–95 (1995).
   PubMed Web of Science ®Google Scholar
• Zhu J, Guo SZ, Beggs AH et al. Microsatellite instability analysis of primary brain tumors. Oncogene12, 1417–1423 (1996).
   PubMed Web of Science ®Google Scholar
• Reifenberger J, Reifenberger G, Liu L et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am. J. Pathol.145, 1175–1190 (1994).
   PubMed Web of Science ®Google Scholar
• Louis DN, Gusella JF. A tiger behind many doors: multiple genetic pathways to malignant glioma. Trends Genet.10, 412–415 (1995).
   Google Scholar
• Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst.90, 1473–1479 (1998).
   PubMed Web of Science ®Google Scholar
• Di Rocco F, Carroll RS, Zhang J et al. Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery42, 341–345 (1998).
   PubMed Web of Science ®Google Scholar
• Chan ASY, Leung SY, Wong MP et al. Expression of vascular endothelial growth factor and it’s receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am. J. Surg. Pathol.22, 816–826 (1998).
   PubMed Web of Science ®Google Scholar
• Fallon KB, Palmer CA, Roth KA et al. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J. Neuropathol. Exp. Neurol.63(4), 314–322 (2004).
   PubMed Web of Science ®Google Scholar
• Walker C, du Plessis DG, Joyce KA et al. Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann. Neurol.57(6), 855–865 (2005).
   PubMed Web of Science ®Google Scholar
• Rubinstein LJ. Oligodendrogliomas. Tumors of the Central Nervous System. Armed Forces Institute of Pathology, DC, USA, 85–104 (1972).
   Google Scholar
• Burger PC, Scheithauer BW, Vogel F. Oligodendroglioma. Surgical Pathology of the Nervous System and its Coverings. John Wiley & Sons, NY, USA, 306–327 (2002).
   Google Scholar
• Coons SW, Johnson PC, Scheithauer BW et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer79(7), 1381–1393 (1997).
   PubMed Web of Science ®Google Scholar
• Lee YY, Van Tassel P. Intracranial oligodendrogliomas: imaging findings in 35 untreated cases. AJNR10, 119–127 (1989).
   Web of Science ®Google Scholar
• Lote K, Egeland T, Hager B et al. Prognostic significance of CT contrast enhancement within histological subgroups of intracranial glioma. J. Neurooncol.40, 161–170 (1998).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Murovic JA, Levin VA. Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology38(9), 1371–1374 (1988).
   PubMed Web of Science ®Google Scholar
• Lee C, Duncan VW, Young AB. Magnetic resonance features of the enigmatic oligodendroglioma. Invest. Radiol.33, 222–231 (1998).
   PubMed Web of Science ®Google Scholar
• Derlon JM, Petit-Taboue MC, Chapon F. The in vivo metabolic pattern of low grade brain gliomas: a positron emission tomography study using 18-F-fluorodeoxyglucose and 11C-L-methylmethionine. Neurosurgery40, 276–287 (2000).
   Google Scholar
• Reifenberger G, Kros JM, Burger P, Louis DN, Collins VP. Oligodendroglioma. In:World Health Organization classification of tumours. Pathology and genetics of tumours of the nervous system Kleihaus P, Cavenee WK (Eds). IARC Press, Lyon, France, 55–70 (1997).
   Google Scholar
• Burger PC, Rawlings CE, Cox EB et al. Clinicopathologic correlations in the oligodendroglioma. Cancer59, 1345–1352 (1987).
   PubMed Web of Science ®Google Scholar
• Ludwig CL, Smith MT, Godfrey AD, Armbrustmacher VW. A clinicopathological study of 323 patients with oligodendrogliomas. Ann. Neurol.19, 15–21 (1986).
   PubMed Web of Science ®Google Scholar
• Kros JM, Pieterman H, van Eden CG et al. Oligodendroglioma: the Rotterdam-Dijksigt experience. Neurosurgery34, 959–966 (1994).
   PubMed Web of Science ®Google Scholar
• Celli P, Nofrone I, Palma L et al. Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery35, 1018–1035 (1994).
   PubMed Web of Science ®Google Scholar
• Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Ann. Neurol.31, 431–436 (1992).
   PubMed Web of Science ®Google Scholar
• McCormack BM, Miller DC, Budzilovich GN et al. Treatment and survival of low-grade astrocytoma in adults 1977–1988. Neurosurgery31, 636–642 (1992).
   PubMed Web of Science ®Google Scholar
• Muller W, Afra D, Schroder R. Supratentorial recurrences of gliomas. Morphological studies in relation to time intervals with astrocytomas. Acta Neurochir. (Wien)37, 75–91 (1977).
   Google Scholar
• Muller W, Afra D, Schroder R. Supratentorial recurrences of gliomas. Morphological studies in relation to time intervals with oligodendrogliomas. Acta Neurochir. (Wien)39, 15–25 (1977).
   Google Scholar
• Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology54, 1442–1448 (2000).
   PubMed Web of Science ®Google Scholar
• Germano IM, Ito M, Cho KG et al. Correlation of histopathological features and proliferative potential of gliomas. J. Neurosurg.70, 701–706 (1989).
   PubMed Web of Science ®Google Scholar
• Whitton AC, Bloom HJ. Low grade glioma of the cerebral hemispheres in adults: a retrospective analysis of 88 cases. Int. J. Radiat. Oncol. Biol. Phys.18, 783–786 (1990).
   PubMed Web of Science ®Google Scholar
• North CA, North RB, Epstein JA et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation therapy. Cancer66, 6–14 (1990).
   PubMed Web of Science ®Google Scholar
• Shaw EG, Evans RG, Scheithauer BW et al. Postoperative radiotherapy of intracranial ependymoma in pediatric and adult patients. Int. J. Radiat. Oncol. Biol. Phys.13, 1457–1462 (1987).
   PubMed Web of Science ®Google Scholar
• Laws ER, Taylor WF, Clifton MB et al. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J. Neurosurg.61, 665–673 (1984).
   PubMed Web of Science ®Google Scholar
• Medbery CA, Straus KL, Steinberg SM et al. Low-grade astrocytomas: treatment results and prognostic variables. Int. J. Radiat. Oncol. Biol. Phys.15, 837–841 (1988).
   PubMed Web of Science ®Google Scholar
• Soffietti R, Chio A, Giordana MT et al. Prognostic factors in well-differentiated cerebral astrocytomas in the adult. Neurosurgery24, 686–692 (1989).
   PubMed Web of Science ®Google Scholar
• Smith DF, Hutton JL, Sandemann D et al. The prognosis of primary intracerebral tumours presenting with epilepsy: the outcome of medical and surgical management. J. Neurol. Neurosurg. Psychiatry54, 915–920 (1991).
   PubMed Web of Science ®Google Scholar
• Hutton JL, Smith DF, Sandemann D et al. Development of prognostic index for primary supratentorial intracerebral tumours. J. Neurol. Neurosurg. Psychiatry55, 271–274 (1992).
   PubMed Web of Science ®Google Scholar
• Vecht CJ. Effect of age on treatment decisions in low-grade glioma. J. Neurol. Neurosurg. Psychiatry56, 1259–1264 (1993).
   PubMed Web of Science ®Google Scholar
• Pignatti F, van Den Bent M, Curran D et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J. Clin. Oncol.20, 2076–2084 (2002).
   PubMed Web of Science ®Google Scholar
• Glantz M, Recht LD. Epilepsy in the cancer patient. In: Handbook of Clinical Oncology, Neuro-Oncology–Part III. Vecht CJ (Ed.), Elsevier, Amsterdam, The Netherlands (1997).
   Google Scholar
• Pilcher WH, Sibergeld DL, Berger MS et al. Intraoperative electrocorticography during tumor resection: impact on seizure outcome in patients with gangliogliomas. J. Neurosurg.78, 891–902 (1993).
   PubMed Web of Science ®Google Scholar
• Zentner J, Hufnagel A, Wolf HK et al. Surgical treatment of neoplasms associated with medically intractable epilepsy. Neurosurgery41, 378–386 (1997).
   PubMed Web of Science ®Google Scholar
• Piepmeier J, Baehring JM. Surgical resection for patients with benign primary brain tumors and low grade gliomas. J. Neurooncol.69, 55–65 (2004).
   PubMed Web of Science ®Google Scholar
• Bampoe J, Bernstein M. The role of surgery in low grade gliomas. J. Neurooncol.42, 259–269 (1999).
   PubMed Web of Science ®Google Scholar
• Piepmeier J, Christopher S, Spencer D et al. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery38, 872–878 (1996).
   PubMed Web of Science ®Google Scholar
• Albayrak B, Samdani AF, Black PM. Intra-operative magnetic resonance imaging in neurosurgery. Acta Neurochir. (Wien)146, 543–557 (2004).
   PubMed Web of Science ®Google Scholar
• Claus EB, Horlacher A, Hsu L et al. Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer103, 1227–1233 (2005).
   PubMed Web of Science ®Google Scholar
• Henson JW, Gaviani P, Gonzalez RG. MRI in treatment of adult gliomas. Lancet Oncol.6, 167–175 (2005).
   PubMed Web of Science ®Google Scholar
• van Veelen ML, Avezaat CJ, Kros JM et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J. Neurol. Neurosurg. Psychiatry64, 581–587 (1998).
   PubMed Web of Science ®Google Scholar
• Forsyth PA, Shaw EG, Scheithauer BW et al. Supratentorial pilocytic astrocytomas. A clinicopathologic, prognostic, and flow cytometric study of 51 patients. Cancer72, 1335–1342 (1993).
   PubMed Web of Science ®Google Scholar
• Leibel SA, Sheline GE, Wara WM et al. The role of radiation therapy in the treatment of astrocytomas. Cancer35, 1551–1577 (1975).
   PubMed Web of Science ®Google Scholar
• Vertosick FT, Selker RG, Arena VC. Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography. Neurosurgery28, 496–501 (1991).
   PubMed Web of Science ®Google Scholar
• Garcia DM, Fulling KH, Marks JI. The value of radiation therapy in addition to surgery for astrocytomas of the adult cerebrum. Cancer55, 919–927 (1985).
   PubMed Web of Science ®Google Scholar
• Francesco P, van den Bent M, Curran D et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J. Neurol. Neurosurg.Psychiatry64(5), 581–587 (1998).
   PubMed Web of Science ®Google Scholar
• Karim AB, Afra D, Cornu P et al. Randomized trial on the efficacy of radiotherapy for cerebral low grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council Study BRO4: an interim analysis. Int. J. Radiat. Oncol. Biol. Phys.52(2), 316–324 (2002).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Afra D, de Witte O et al. Long term efficacy of early versus delayed radiotherapy for low grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomized trial. Lancet366(9490), 985–990 (2005).
   PubMed Web of Science ®Google Scholar
• Shaw EG, Tatter SB, Lesser GJ et al. Current controversies in the radiotherapeutic management of adult low grade glioma. Semin. Oncol.31(5), 653–658 (2004).
   PubMed Web of Science ®Google Scholar
• Surma-aho O, Niemela M, Vilkki J et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology56, 1285–1290 (2001).
   PubMed Web of Science ®Google Scholar
• Kiebert GM, Curran D, Aaronson NK et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomized Phase III trial on dose response (EORTC Trial 22844). Eur. J. Cancer34, 1902–1909 (1998).
   PubMed Web of Science ®Google Scholar
• Klein M, Heimans JJ, Aaronson NK et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet360, 1361–1368 (2002).
   PubMed Web of Science ®Google Scholar
• Taphoorn MJ, Schiphorst AK, Snoek FJ et al. Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann. Neurol.36, 48–54 (1994).
   PubMed Web of Science ®Google Scholar
• Brown PD, Buckner JC, O'Fallon JR et al. Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the Folstein mini-mental state examination. J. Clin. Oncol.21, 2519–2524 (2003).
   PubMed Web of Science ®Google Scholar
• Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for Phase II studies of supratentorial malignant glioma. J. Clin. Oncol.8, 1277–1280 (1990).
   PubMed Web of Science ®Google Scholar
• Diabira S, Rousselet MC, Gamelin E et al. PCV chemotherapy for oligodendroglioma: response analyzed on T2 weighted-MRI. J. Neurooncol.55, 45–50 (2001).
   PubMed Web of Science ®Google Scholar
• Perry JR, Cairncross JG. Glioma therapies: how to tell which work? J. Clin. Oncol.21, 3547–3565 (2003).
   PubMed Web of Science ®Google Scholar
• Vos MJ, Hoekstra OS, Barkhof F et al. Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma. J. Clin. Oncol.21, 3559–3565 (2003).
   PubMed Web of Science ®Google Scholar
• Eyre HJ, Crowley JJ, Townsend JJ et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J. Neurosurg.78, 909–914 (1993).
   PubMed Web of Science ®Google Scholar
• Buckner JC, Gesme D Jr, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J. Clin. Oncol.21, 251–255 (2003).
   PubMed Web of Science ®Google Scholar
• Quinn JA, Reardon DA, Friedman AH et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J. Clin. Oncol.21, 646–651 (2003).
   PubMed Web of Science ®Google Scholar
• Brada M, Viviers L, Abson C et al. Phase II study of primary temozolamide chemotherapy in patients with WHO grade II gliomas. Ann. Oncol.14(12), 1715–1721 (2003).
   PubMed Web of Science ®Google Scholar
• Mollemann M, Wolter M, Felsberg J et al. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int. J. Cancer113, 379–385 (2004).
   Web of Science ®Google Scholar
• Cairncross G, Macdonald D, Ludwin S et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.12, 2013–2021 (1994).
   PubMed Web of Science ®Google Scholar
• Soffietti R, Ruda R, Bradac GB et al. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery43, 1066–1073 (1998).
   PubMed Web of Science ®Google Scholar
• Glass J, Hochberg FH, Gruber ML et al. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J. Neurosurg.76, 741–745 (1992).
   PubMed Web of Science ®Google Scholar
• Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology46, 203–207 (1996).
   PubMed Web of Science ®Google Scholar
• Allison RR, Schulsinger A, Vongtama V et al. Radiation and chemotherapy improve outcome in oligodendroglioma. Int. J. Radiat. Oncol. Biol. Phys.37, 399–403 (1997).
   PubMed Web of Science ®Google Scholar
• Stege EM, Kros JM, de Bruin HG et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer103, 802–809 (2005).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Taphoorn MJ, Brandes AA et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J. Clin. Oncol.21, 2525–2535 (2003).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Keime-Guibert F, Brandes AA et al. Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology57, 340–342 (2001).
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J. Clin. Oncol.22, 3133–3138 (2004).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Salvage chemotherapy with CPT 11 for recurrent oligodendrogliomas. J. Neurooncol.59(2), 157–163 (2002).
   PubMed Web of Science ®Google Scholar
• Peterson K, Paleologos N, Forsyth P et al. Salvage chemotherapy for oligodendroglioma. J. Neurosurg.85(4), 597–601 (1996).
   PubMed Web of Science ®Google Scholar
• Soffietti R, Nobile M, Ruda R et al. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a Phase II study. Cancer100(4), 807–813 (2004).
   PubMed Web of Science ®Google Scholar
• Mork SJ, Lindergaard KF, Halvorsen TB et al. Oligodendroglioma: incidence and biological behavior in a defined population. J. Neurosurg.63, 881–889 (1985).
   PubMed Web of Science ®Google Scholar
• Celli P, Nofrone I, Palma L et al. Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery35, 1018–1034 (1994).
   PubMed Web of Science ®Google Scholar
• Weir B, Allen PB, Miller JD et al. Oligodendrogliomas: An analysis of 63 cases. J. Neurosurg.29, 500–504 (1968).
   Web of Science ®Google Scholar
• Reiche W, Grunwald I, Hermann K. Oligodendrogliomas. Acta Radiol.43(5), 474–482 (2002).
   PubMed Web of Science ®Google Scholar
• Chang SM, Parney IF, Huang W et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA2, 293(5), 557–564 (2005).
   Google Scholar
• Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J. Clin. Oncol.6(2), 338–343 (1988).
   PubMed Web of Science ®Google Scholar
• Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg.95(2), 190–198 (2001).
   PubMed Web of Science ®Google Scholar
• Gallia GL, Brem S, Brem H. Local treatment of malignant brain tumors using implantable chemotherapeutic polymers. J. Natl. Compr. Can. Netw.3(5), 721–728 (2005).
   Google Scholar
• Quigley MR, Maroon JC. The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery29(3), 385–388 (1991).
   PubMed Web of Science ®Google Scholar
• Cairncross G, Seiferheld W, Shaw E et al. An Intergroup Randomized Controlled Clinical Trial (RCT) of Chemotherapy plus Radiation (RT) versus RT alone for Pure and Mixed Anaplastic Oligodendrogliomas: Initial Report of RTOG 94–02. In abstract form presented at ASCO (2004).
   Google Scholar
• van den Bent MJ, Delattre J, Brandes AA et al. First analysis of EORTC trial 26951, a randomized Phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma. In abstract form presented at ASCO (2005).
   Google Scholar
• Abrey LE, Childs BH, Paleologos N et al. High dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. J. Neurooncol.65(2), 127–134 (2003).
   PubMed Web of Science ®Google Scholar
• Bouffet E, Jouvet A, Thiesse P et al. Chemotherapy for aggressive or anaplastic high grade oligodendrogliomas and oligoastrocytomas: better than a salvage treatment. Br. J. Neurosurg.12, 217–222 (1998).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology51, 1140–1150 (1998).
   PubMed Web of Science ®Google Scholar
• Cairncross G, MacDonald D, Ludwin S et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.12, 2013–2021 (1994).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Tosoni A, Vastola F et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer1, 101(9), 2079–2085 (2004).
   Google Scholar
• Chinot O. Chemotherapy for the treatment of oligodendroglial tumors. Semin.Oncol.28(4 Suppl.13), 13–18 (2001).
   PubMedGoogle Scholar
• van den Bent MJ, Keime-Guibert F, Brandes AA et al. Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology24, 57(2), 340–342 (2001).
   Google Scholar
• Pace A, Vidiri A, Galie E et al. Temozolamide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann. Oncol.14(12), 1695–1696 (2003).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.10, 352(10), 987–996 (2005).
   Google Scholar